DNV Capital

Cyrano Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for individuals suffering from taste and smell disorders. Founded in 2014 and based in Washington, D.C., the company is working on an intranasal product, CYR-001, which repurposes an existing approved molecule, Theophylline, to restore sensory function in patients experiencing chronic loss of taste and smell. In preliminary studies, CYR-001 demonstrated promising results, with eight out of ten participants showing significant improvements within two weeks and no reported side effects. The company's approach includes a diagnostic kit designed to assess and quantify the severity of sensory loss, thereby aiding caregivers in enhancing the quality of life for affected patients, including those undergoing chemotherapy who often experience changes in their sensory perception.

Chengdu Tianrui Xingtong Technology specializes in active phased array semiconductors and antennas for microwave and millimeter waves. Chengdu Tianruixingtong has been actively engaged in the field of millimeter wave-phased arrays. It has developed a number of mass-produced products and has extensive engineering experience in the production of phased array test equipment, modules, and antenna components.

Beijing Surgerii Technology Co., Ltd. specializes in the research, development, production, and sale of minimally invasive surgical robot systems in China. Founded in 2014 and based in Beijing, the company focuses on innovative technologies, particularly the next generation of flexible continuum robotic arms. Surgerii Technology aims to transform clinical practices through its single-hole and porous laparoscopic robot systems, enhancing the standard of care in minimally invasive surgeries. With a commitment to independent research and development, the company leverages its expertise in system design and integration to advance the medical equipment industry in China.

Sanoculis is an Israeli medical device company founded in 2012. It specializes in developing innovative surgical procedures for treating glaucoma. Its flagship product, Minimally Invasive Micro Sclerostomy (MIMS), consists of a single-use sterile tool and a multi-use external machine. MIMS creates a sclero-corneal drainage channel to reduce intraocular pressure, minimizing tissue trauma and scar formation.

Sinovation Medical specializes in the development of advanced medical robot technology and intelligent medical products. The company designs innovative medical devices aimed at delivering enhanced precision care. Their surgical robots employ clinical computer visioning technology to offer precise solutions for doctors and medical institutions. These products are primarily used in neurosurgery, addressing conditions such as epilepsy, Parkinson's disease, cerebral hemorrhage, and intracranial tumors. Sinovation Medical provides reliable medical robotics to clients, focusing on improving the accuracy and effectiveness of surgical procedures.

Wuhan Binhui Biotechnology Co., Ltd., established in 2010 and headquartered in Wuhan, China, specializes in the development of virus injection preparations. Situated in the Optics Valley Bio City within the Donghu National Independent Innovation Demonstration Zone, the company focuses on creating innovative products and services in the oncology sector, encompassing both diagnosis and treatment. Binhui Biotech is dedicated to developing offerings with independent intellectual property rights, aiming to compete effectively on the international market.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Hinova Pharmaceuticals Inc. is a drug discovery and development company based in Chengdu, China, with additional branches in Hong Kong, Texas, and Australia. Established in 2013, the company specializes in the research and manufacturing of innovative medicines to address unmet medical needs, particularly in oncology and metabolic diseases. Utilizing advanced technology platforms such as deuterium and PROTAC, Hinova develops both Best-in-class and First-in-class drugs. Its product pipeline includes the HC-1119 androgen receptor antagonist and HC-1102 androgen receptor inhibitors, which target advanced prostate cancer and breast cancer. The company's commitment lies in providing safe, effective, and affordable treatments while retaining global rights and interests in its drug portfolio.

Geneseeq Technology Inc., founded in 2008 and based in Toronto, Canada, is a clinical testing and diagnostic center specializing in next-generation sequencing (NGS) technologies for precision medicine in cancer treatment. The company's platform translates patients' genomic information into decision-making tools for physicians and cancer patients. Geneseeq's laboratories have achieved numerous qualifications, including passing assessments from the China’s National Center of Clinical Laboratories, College of American Pathologists, and European Molecular Genetics Quality Network.

Sonendo is a commercial-stage medical technology company that develops dental devices and software to save teeth. It markets the GentleWave System, a root canal therapy platform that cleans and disinfects the microscopic spaces within teeth without removing tooth structure, improving clinical outcomes and practice efficiency. The system includes a console and accessories and integrates with TDO Software, its endodontic practice management software that unifies imaging, practice management, referral reporting, CBCT imaging, and built-in communication with the GentleWave System. Founded in 2006 and based in Laguna Hills, California, Sonendo operates with two business segments: Product, comprising the GentleWave console and instruments, and Software, providing practice management licenses. The company aims to transform dentistry by saving teeth through sound science.

JFK Biotech develops products for molecular diagnosis and rapid self-test technology. They also offer a series of products for early screening, early diagnosis, and early treatment of pulmonary nodules, lung cancer, COPD, asthma, airway inflammation, and airway infection.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Human Xtensions Ltd. is a company based in Netanya, Israel, that specializes in developing handheld digital solutions for minimally invasive surgery (MIS). Founded in 2012, the company focuses on creating unmediated surgical systems that integrate the advantages of robotics with the functionality of ergonomic handheld tools. Its flagship product, HandX, is a lightweight device that enables surgeons to translate their natural hand movements into complex actions during laparoscopic procedures, thereby enhancing precision and control in surgery. Through its innovative approach, Human Xtensions aims to improve surgical outcomes and streamline the surgical process.

TruTag Technologies, Inc. is a technology company specializing in precision-fabricated nano-porous silica for applications in drug delivery, product authentication, and data intelligence. The company has developed TruTag, an edible microtag aimed at identifying, authenticating, and ensuring the quality of medicines, medical products, food items, and consumer goods. This innovation helps mitigate issues such as counterfeiting, product diversions, and quality control, serving various industries including healthcare, life sciences, food and beverages, and electronics. TruTag Technologies operates a state-of-the-art manufacturing facility in Hawaii and has engineering offices in California, with additional business development offices across the United States and in Scotland. The company has garnered recognition for its technological advancements, including accolades from the SPIE Prism Awards and the Edison Awards, and has been acknowledged by the World Economic Forum as a Technology Pioneer.

Vessix Vascular, Inc. is a privately-held medical device company focused on developing innovative catheter-based technologies. The company's primary product, the ZCath® System, utilizes radiofrequency balloon catheter technology to treat high blood pressure by targeting and deadening nerves near the kidneys. This approach aims to provide an effective solution for reducing plaque in peripheral leg arteries. Vessix Vascular is currently in the pre-revenue stage and has achieved a CE Mark for its initial product, indicating its compliance with European health and safety standards.